In a matter of weeks, COVID-19 changed our lives. As the outbreaks impact on public health, the economy and even our daily lives becomes increasingly evident, so does the importance of the biotechnology and life sciences sector. Public officials, regulators and citizens are turning to biotechnology for solutions.

The industry has responded with unprecedented speed to the emerging health threat, spearheading the search for vaccines, antiviral treatments, and diagnostic tools. The pandemic has also highlighted the critical need to reduce our ecological footprint by transitioning to a circular economy using biotechnology solutions.

Today, the European Commission is setting the course for Europes recovery from the pandemic, driven by the European Green Deal and its associated Industrial, Pharmaceutical, Farm to Fork and Digital strategies.

The time is now right for a strong EU Life Sciences and Biotechnology strategy, and for this sector to show that key global challenges like pandemic preparedness, health and well-being, global warming and destruction of biodiversity can be addressed through transformative solutions.

Never has biotechnology been better positioned to contribute to a more inclusive economy; creating the jobs of the future that younger generations need to participate in the economic recovery and help us transition to a decarbonised green, biobased, and circular economy, while also creating resilient ecosystems for the health and well-being of us all.

In a time of great scientific advancement and innovation, the EU needs to remain competitive on the world stage. Therefore, we must unleash the full potential of the EUs life sciences and biotechnology.

During this years European Biotech Week (28 September 4 October), EuropaBio, the European Association of Bioindustries, together with Members of the European Parliament Juozas Olekas (LT, S&D) and Maria Spyraki (EL, EPP), launched its vision for a European life science and biotechnology strategy, entitled Unleashing the full potential of life sciences and biotechnology in Europe.

At the event, speakers from Royal DSM (Marcus Remmers, Chief Technology Officer) and Kite Pharma (Dick Sundh, Head of Europe) presented innovative biotech solutions that contribute to the sustainability and health of global societies both today and in the future. Find out more about the event here.

Never has biotechnology been better positioned to contribute to a more inclusive economy; creating the jobs of the future that younger generations need to participate in the economic recovery

EuropaBios vision document outlines eight key pillars through which life sciences and biotechnology can help us transform Europe into a healthier, more resilient, and more sustainable continent, one that can swiftly recover from the current crisis and deliver for its citizens, regions and economy.

Investing in a strong life sciences and biotechnology ecosystem will be essential to creating the innovation engine that Europe needs. Few other industries directly provide for our health and sustainability while simultaneously stimulating investment, innovation and employment.

Empowering the biotechnology industry ensures support for SMEs and offers a host of indirect opportunities for growth across manufacturing, supply chains, education and research.

The stronger our life sciences and biotechnology ecosystem, the better prepared Europe will be to confront future global challenges.

Our ambitious vision for the life sciences and biotechnology sector provides a strategic way forward to underpin the European Green Deal and its associated strategies. Together we can accelerate the realisation of our common goals of healthy people and a sustainable planet.

Read the rest here:
Unleashing the full potential of life sciences and biotechnology in Europe - The Parliament Magazine

SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of preclinical research in an influenza animal model highlighting a new mechanism for enhancing the efficacy of monoclonal antibodies to treat viral infection and induce a protective response. Data demonstrate that selective engagement of an activating Fc receptor on dendritic cells by antiviral monoclonal antibodies induced protective CD8+ T cell adaptive responses. The paper, entitled Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection, was published in the October 8, 2020 online edition of Nature.

In the past several years, we've gained a better understanding of how integral Fc mediated effector functions of monoclonal antibodies are for their therapeutic efficacy in pre-clinical models of neoplastic, infectious and inflammatory diseases, said Jeffrey V. Ravetch, M.D., Ph.D., study senior author and Theresa and Eugene M. Lang Professor and Head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at The Rockefeller University. These approaches have been successfully applied to anti-tumor therapeutics and have resulted in improved clinical outcomes in a variety of oncologic diseases. Our present studies have uncovered a significant new mechanism by which antibodies, through their Fc region, can not only engage innate immune responses but activate adaptive T cell responses, thereby stimulating protective anti-viral immunity in these models.

The research published in Nature focuses on the role of the Fc domain of monoclonal antibodies, regions with the capacity to bind to other immune cells through a family of receptors (the Fc receptors). By engineering antibodies with modified Fc domains to enhance binding to specific Fc receptors on innate immune cells, investigators observed an enhanced protective immune response. Certain modifications (GAALIE variants) were associated with activation of dendritic cells, as well as antiviral effector T-cells, indicating induction of the adaptive arm of the immune system, which is responsible for long-term immunity. Based on this research, monoclonal antibodies programmed with improved effector function represent a potential new approach in the design of therapeutic antibodies for both the prevention and treatment of infectious diseases.

By observing and learning from our bodys powerful natural defenses, we have discovered how to maximize the capacity of antibodies through the amplification of key characteristics that may enable more effective treatments for viral diseases, said Herbert Skip Virgin, M.D., Ph.D., study co-author and executive vice president, research, and chief scientific officer of Vir. These data may have significant implications across a wide range of infectious diseases, and we look forward to exploring the vaccinal potential of the GAALIE-engineered antibodies we are advancing through clinical development VIR-3434 for chronic hepatitis B and VIR-7832 for SARS-CoV-2.

The preclinical study was conducted by Dr. Ravetch and Stylianos Bournazos, Ph.D., of the Laboratory of Molecular Genetics and Immunology at The Rockefeller University, in collaboration with Dr. Virgin and Davide Corti, Ph.D., senior vice president of antibody research at Virs subsidiary Humabs BioMed SA.

This type of exceptional collaborative partnership between cutting-edge science and clinical application has the potential to significantly improve our ability to address infectious diseases, stated Dr. Virgin.

Vir is currently evaluating several monoclonal antibodies that have been Fc engineered to include the XX2 vaccinal mutation (or GAALIE variant) for which Vir has licensed exclusive rights for all infectious diseases.

About VIR-3434VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes and also to reduce the level of virions and subviral particles in the blood. VIR-3434 has been engineered to have an extended half-life as well as to potentially function as a T cell vaccine against HBV in infected patients.

About VIR-7832VIR-7832 is a monoclonal antibody that has shown the ability to neutralize SARS-CoV-2 live virus in vitro. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (also known as SARS), indicating that the epitope is highly conserved, which may make it more difficult for escape mutants to develop. VIR-7832 has been engineered with the potential to enhance lung bioavailability, have an extended half-life, and function as a therapeutic and/or prophylactic T cell vaccine. VIR-7832 is being developed by Vir and its partner GlaxoSmithKline plc(LSE/NYSE: GSK) as part of their broader collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2.

About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis. For more information, please visitwww.vir.bio.

Vir Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as potential, may, will, could, expect, plan, anticipate, believe, estimate, goal, intend, candidate, continuing, developing and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the ability of enhanced Fc mediated effector functions in enhancing the efficacy of monoclonal antibodies to treat viral infections and inducing a protective response in animal models, using an oncological therapeutic approach and enhanced effector function in the treatment of infectious diseases, the vaccinal potential of specifically engineered antibodies in the treatment of chronic hepatitis B and SARS-CoV-2, and statements around the companys plans to explore the vaccinal potential of engineered antibodies as it advances through clinical development of VIR-3434 for the treatment of chronic hepatitis B and VIR-7832 for SARS-CoV-2. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in treating chronic hepatitis B and neutralizing SARS-CoV-2, difficulty in collaborating with other companies or government agencies, and challenges in accessing manufacturing capacity. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with theU.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Read more here:
Nature Publishes New Research from Vir Biotechnology Demonstrating the Capacity of Enhanced Monoclonal Antibodies to Induce Protective Adaptive...

MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the BIO Investor Forum, being held virtually on October 13-15, 2020. This presentation will be available on demand for BIO Investor attendees.

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

About CohBar

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBars founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome,some of whichhave been shown tohave the potential to regulatekey processes inmultiplesystems andorgans in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBars efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseasesbecause of the underlying impact of mitochondrial dysfunction. The companys lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity. In addition, CohBarhas four preclinical programs: CB5138 Analogs for fibrotic diseases,CB5064 Analogs for COVID-19 associated ARDS, MBT5 Analogs for CXCR4-related cancer and orphan diseases, and MBT3 Analogs for cancer immunotherapy.

For additional company information, please visit http://www.cohbar.com.

Forward-Looking Statements

This news release contains forward-looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as believe, may, will, estimate, continue, anticipate, intend, could, should, would, project, plan, expect, goal, seek, future, likely or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to statements regarding anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs, MBTs and other potential therapies. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable than and that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; the risk that our intellectual property may not be adequately protected; our ability to establish and maintain partnerships with corporate and industry partners; and risks related to the impact on our business of the COVID-19 pandemic or similar public health crises. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at http://www.sec.gov orwww.sedar.com.

You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

Contacts: Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650) 445-4441Jordyn.tarazi@cohbar.com

Joyce AllaireLifeSci Advisors, LLCjallaire@lifesciadvisors.com

Go here to read the rest:
CohBar to Present at the BIO Investor Forum - GlobeNewswire

A rating of 30 puts Ionis Pharmaceuticals Inc (IONS) near the bottom of the Biotechnology industry according to InvestorsObserver. Ionis Pharmaceuticals Inc's score of 30 means it scores higher than 30% of stocks in the industry. Ionis Pharmaceuticals Inc also received an overall rating of 38, putting it above 38% of all stocks. Biotechnology is ranked 27 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 38 would rank higher than 38 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Ionis Pharmaceuticals Inc (IONS) stock is trading at $46.79 as of 1:16 PM on Monday, Oct 5, an increase of $1.13, or 2.49% from the previous closing price of $45.65. The stock has traded between $46.04 and $47.20 so far today. Volume today is 1,079,820 compared to average volume of 926,841.

Click Here to get the full Stock Score Report on Ionis Pharmaceuticals Inc (IONS) Stock.

Visit link:
Where Does Ionis Pharmaceuticals Inc (IONS) Stock Fall in the Biotechnology Field? - InvestorsObserver

Reportspedia added a new research report to its exhaustive repository. The research report presents an unbiased approach to understanding the market trends and dynamics of the Agriculture Biotechnology Market. Analysts have studied the past data pertaining to the market and compare it to the up-to-date market trends to paint an objective picture of the trajectory of the market. The Agriculture Biotechnology report includes SWOT analysis and Porters five forces analysis to give the readers a comprehensive estimation of the various factors likely to drive and restrain the overall market.

Key Player Mentioned:

ADAMA Agricultural SolutionsVilmorinBayerBiocentury TransgeneCertisDow AgroSciencesEurofinsEvogeneGlobal Bio-chem TechnologySyngentaKWS SaatMarina BiotechMonsanto

Get Exclusive Sample Report on Agriculture Biotechnology Marketis available at:

https://www.reportspedia.com/report/life-sciences/global-agriculture-biotechnology-market-research-report-2020-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/54704#request_sample

Regional Segment Analysis:North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain etc.), Asia-Pacific (China; India; Japan; Southeast Asia etc.), South America (Brazil; Argentina etc.), Middle East & Africa (Saudi Arabia; South Africa etc.)

Global Agriculture Biotechnology Industry Market provides a 360-degree outlook of the market for advanced technologies, key drivers, regulatory and future trends for brief to medium-term and long-term predict period. This Agriculture Biotechnology Market report study market size, industry conditions, and forecasts, competitive landscape, and growth opportunities.

The Global Agriculture Biotechnology Market Report has been Segments into:

Global Agriculture Biotechnology Market Size & Share, By Product Types,

BiochipsDeoxy ribonucleic acid (DNS) sequencingGenome editing toolsRibonucleic acid interference (RNAI)Synthetic biology

Global Agriculture Biotechnology Market Size & Share, By Applications,

Transgenic crops marketSynthetic biology-enabled products market

Inquire before Buying at:

https://www.reportspedia.com/report/life-sciences/global-agriculture-biotechnology-market-research-report-2020-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/54704#inquiry_before_buying

Global Agriculture Biotechnology Market competitive landscape supplies details by vendors, including company overview, total business revenue (financials), market potential, international existence, Keyword sales, and earnings generated, market share, cost, production sites and centers, SWOT analysis, product launch. During the period of 2020-2026, this analysis provides the sales, market share for each player enclosed in this report.

Ask For Discount at:

https://www.reportspedia.com/discount_inquiry/discount/54704

Key questions answered in the report:

The Report Provides:

Key features of this report are:

Get the Sample ToC at:

https://www.reportspedia.com/report/life-sciences/global-agriculture-biotechnology-market-research-report-2020-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/54704#table_of_contents

More here:
Global Agriculture Biotechnology Market 2020 by Manufacturers,Demand,Size,Regions, Type and Application, Forecast to 2026 - Crypto Daily

Find your path into a rewarding biotech or biomanufacturing job in Maryland through this Fall Symposium Series.

Montgomery College has kicked off a virtual fall symposium series to highlight the booming Maryland biotech industry and the education and training options available for people interested in biotechnology employment.

The series started on September 28th and will run through October 26th, 2020. Montgomery College has played a pivotal workforce development role in the BioHealth Capital Region (BHCR); in addition to its flagship Associates in Biotechnology degree and Biomanufacturing certificate programs, the colleges Bio-Trac and BioTrain hands-on workshops and seminars have prepared scores of individuals for biotech careers, augmented existing biotech workers skill sets and taught the latest advanced research skills to further their respective careers.

The symposium is a joint effort by Montgomery College, Frederick Community College, and The University of Maryland, Baltimore County (UMBC) to provide training and to educate students about career opportunities in the regions life science industry. The symposium is bringing together these institutions as well as prominent leaders from the BHCR life science ecosystem for a series of five training and educational sessions.

You may like -> Explore BioManufacturing Jobs in Maryland

Sessions will be held virtually from 4:00 to 4:45 pm on select Mondays. The first session was held on September 28th, but there are more sessions available. To register for a session, click here.

Applying For A Job in Biotechnology | Monday, October 5

Learn the importance of your resume and the basics of formatting your resume to best represent you and your skill set. In addition, topics covered will include applying for openings, online presence, interview skills, and interview preparation. Presented by Nick Wright, Recruiter, Catalent, Inc.

The Biotechnology Program at Montgomery College | Monday, October 12

Montgomery College Biotech has the largest program in the state and one of the best biotech programs in the country. Take a virtual tour of the program and see why graduates have the MC Biotech Advantage in starting their career. Presented by Dr. Lori Kelman, Biotechnology Education Coordinator & Dr. Collins Jones, Biotechnology Industry Coordinator, at Montgomery College.

What It Takes To Work In A Biotech Company | Monday, October 19

Learn about Frederick Community Colleges biotech program and hear from students what it is like and what it takes to work in a biotech company. Presented by Dr. Savita Prabhakar, Program Manager of Biotechnology at Frederick Community College.

The Translational Life Science Technology (TLST) Program at UMBC | Monday, October 26

Take a virtual tour of the new TLST laboratory facilities and find out how a BS degree in applied biotechnology can work for you. Presented by Dr. Elizabeth Friar, Program Director of TLST at UMBC-Shady Grove.

Registration is still open. To register for a session, click here. Following the submission of your RSVP, the Zoom link to these sessions will be provided via email a few days in advance of each session.

Workforce development programs at Montgomery College, Frederick Community College, UMBC and other institutions continue to inspire students to pursue careers in the life sciences and to develop the life science talent of the future, which is critical to the continued, sustained success of the BHCR biohealth cluster.

Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.

Here is the original post:
Learn How to Get a Job in the Biotech Industry with this Free Virtual Webinar Series Hosted by Montgomery College - BioBuzz

A rating of 71 puts Constellation Pharmaceuticals Inc (CNST) near the top of the Biotechnology industry according to InvestorsObserver. Constellation Pharmaceuticals Inc's score of 71 means it scores higher than 71% of stocks in the industry. Constellation Pharmaceuticals Inc also received an overall rating of 59, putting it above 59% of all stocks. Biotechnology is ranked 27 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 59 would rank higher than 59 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Constellation Pharmaceuticals Inc (CNST) stock is trading at $21.92 as of 1:01 PM on Friday, Oct 2, a drop of -$0.94, or -4.11% from the previous closing price of $22.86. The stock has traded between $21.54 and $22.42 so far today. Volume today is light. So far 225,100 shares have traded compared to average volume of 565,319 shares.

Click Here to get the full Stock Score Report on Constellation Pharmaceuticals Inc (CNST) Stock.

Continue reading here:
Is Constellation Pharmaceuticals Inc (CNST) a Winner in the Biotechnology Industry? - InvestorsObserver

The latest report titled Global Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Status and Forecast 2020-2026 aims to enhance your decision-making ability in the business by providing knowledgeable insights related to the market and competitive landscape. The report recognizes vital facts, events, and possible variations in the global Nanoparticles in Biotechnology and Pharmaceuticals market. The report depicts valuable insights related to significant market trends driving the industry. It highlights key opportunities and challenges faced by market leaders while assessing their competitive setting and corporate strategies for the estimated timeline. The report also reveals drivers, trends, the market scope, profitability, demand status, uncertainties, and development forecast from 2020 to 2026 time-period.

The report covers SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. The research studies the global Nanoparticles in Biotechnology and Pharmaceuticals market competition, leading companies, industry environment, emerging opportunities, trends, and crucial segments in the market. Then the study encompasses company profiles, size, production value, product specifications, capacity, and 2020-2026 market shares occupied by each company. The global market size & trends are classified based on the types of products, application segments, and end-user. Each segment expansion is assessed together with the estimation of their growth in the upcoming period.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/23602/request-sample

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Key Segments Studied In The Report:

For competitor segment, the report includes global key players of the market as well as some small players: Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire,

Segment by product type, this report focuses on consumption, market share, and growth rate of the market in each product type and can be divided into:

Segment by application, this report focuses on consumption, market share, and growth rate of the market in each application and can be divided into: Biotechnology, Pharmaceutical,

The important geographical segments of the global Nanoparticles in Biotechnology and Pharmaceuticals market are as follows: North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa).

Production and consumption Analysis of The Global Nanoparticles in Biotechnology and Pharmaceuticals Market:

One part is about its production and the other part is about its consumption. On the basis of its production, the report analyzes the production, revenue, gross margin of its main manufacturers, and the unit price that they offer in different regions from 2015 to 2019. In terms of consumption, we analyze the consumption volume, consumption value, sale price, import, and export in different regions from 2015 to 2019. We also make a prediction of its production and consumption in the coming 2020-2026.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-nanoparticles-in-biotechnology-and-pharmaceuticals-market-size-23602.html

Key Report Pointers & Highlights:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.magnifierresearch.com

Read the original:
Global Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2026 - The...

The 65 rating InvestorsObserver gives to Anavex Life Sciences Corp (AVXL) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 81 percent of stocks in the Biotechnology industry, AVXLs 65 overall rating means the stock scores better than 65 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Anavex Life Sciences Corp (AVXL) stock is trading at $4.01 as of 1:12 PM on Friday, Oct 2, a loss of -$0.22, or -5.32% from the previous closing price of $4.23. The stock has traded between $3.95 and $4.17 so far today. Volume today is 516,626 compared to average volume of 636,483.

Click Here to get the full Stock Score Report on Anavex Life Sciences Corp (AVXL) Stock.

Go here to see the original:
Is Anavex Life Sciences Corp (AVXL) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Executive summary:

The latest report on Biotechnology Separation Systems market strives to provide a conclusive overview of the current and future market scenario with respect to the key growth catalysts, challenges, and opportunities across the various geographies.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/6449

The Biotechnology Separation Systems market is projected to expand with a CAGR of XX% during the forecast period 2020-2025.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/6449

In addition to region wise-assessment, the study also draws attention towards the competitive landscape by profiling the top contenders in the industry. A complete analysis of the various market segmentation is underlined in the report. Additionally, a detailed visualization of the global Covid-19 impact on the growth matrix of this business space is provided.

Market synopsis:

Regional outlook:

Product terrain outline:

Application spectrum overview:

Competitive landscape review:

Additional information from the Biotechnology Separation Systems market report:

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Market segmentation

The Biotechnology Separation Systems market is split by Type and by Application. For the period 2020-2025, the growth among segments provides accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Research Objective:

Why to Select This Report:

The research process begins with internal and external sources to obtain qualitative and quantitative information related to the Biotechnology Separation Systems market. It also provides an overview and forecast for the Biotechnology Separation Systems market based on all the segmentation provided for the global region. The predictions highlighted in the Biotechnology Separation Systems market share report have been derived using verified research procedures and assumptions. By doing so, the research report serves as a repository of analysis and information for every component of the Biotechnology Separation Systems market.

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/6449

See more here:
Biotechnology Separation Systems Market Analysis, Revenue, Share, Growth Rate & Forecast To 2025 - The Research Process

Latest Research Report: Epimedium Extract industry

Epimedium Extract Market report is to provide accurate and strategic analysis of the Profile Projectors industry. The report closely examines each segment and its sub-segment futures before looking at the 360-degree view of the market mentioned above. Market forecasts will provide deep insight into industry parameters by accessing growth, consumption, upcoming market trends and various price fluctuations.

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Epimedium Extract Market competition by top manufacturers as follow: , Natural Poland, Naturalin BIO-Resources, Xian Sangherb Bio-Tech, Shanghai Zhiqi Biotechnology, Fushun Haoyuan Biological Technology, Xian FengZu Biological Technology, Nutra Green Biotechnology

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/11438

Global Epimedium Extract Market research reports growth rates and market value based on market dynamics, growth factors. Complete knowledge is based on the latest innovations in the industry, opportunities and trends. In addition to SWOT analysis by key suppliers, the report contains a comprehensive market analysis and major players landscape.The Type Coverage in the Market are: Industrial GradePharmaceutical Grade

Market Segment by Applications, covers:MedicineChemical ProductionOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

To get this report at a profitable rate.: https://reportsinsights.com/discount/11438

Important Features of the report:

Reasons for buying this report:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Epimedium-Extract-Market-11438About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Go here to read the rest:
Epimedium Extract Market Incredible Possibilities, Growth Analysis and Forecast To 2025 | Xian FengZu Biological Technology, Nutra Green Biotechnology...

09/25/2020 | 09:50am EDT

BRAIN Group

Pioneering Bioproducts

Investor Presentation

Zwingenberg, September 15th, 2020

Pioneering Bioproducts.

BRAIN Aktiengesellschaft Zwingenberg Germany http://www.brain-biotech.com +49 (0) 6251-9331-0

1

Safe Harbor Statement

This document may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties, as they relate to future events and are based on current assumptions of the Company, which may not occur at all in the future or may not occur as assumed. They do not represent a guarantee for future results or performance of the Company, and the development of economic and legal conditions may materially differ from the information expressed or implied in the forward-looking statements.

The Company assumes no obligation to update or revise any forward-looking statement contained herein or to adapt them to future events or developments. The information contained in this document has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinion contained herein. The Company or any of its shareholders, affiliates, advisors, employees or representatives shall have no liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its content or otherwise arising in connection with this document.

By accepting this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsibility for forming your own view of the potential future performance of the Company's business.

This presentation speaks as of September 15th, 2020. Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The term "BRAIN", as used in this presentation means B.R.A.I.N. Biotechnology Research and Information Network AG and its affiliates, if not otherwise specified.

Pioneering Bioproducts.

BRAIN Aktiengesellschaft Zwingenberg Germany http://www.brain-biotech.com +49 (0) 6251-9331-0

2

Brain at a Glance

~ 39m

'18/'19 Revenues

> 27

Years of Experience

~ 300

Employees

> 100

Specialty B2B Products

> 100

Industrial Partnerships

2016

Listed, Frankfurt Prime Standard

Creating Breakthrough Bioproducts & Solutions for Nutrition, Health and Environment

Industrial Biotech

Three

(white)

Product Platforms

Enzymes

Microorganisms

Bioactive

Natural

Compounds

From the Lab to Production

Pioneering Bioproducts.

BRAIN Aktiengesellschaft Zwingenberg Germany http://www.brain-biotech.com +49 (0) 6251-9331-0

3

Mission & Vision

"Mission is what an organization is or does. Vision is what an organization desires to become"

Mission

Creating Breakthrough Bioproducts and Solutions for Nutrition, Health and the Environment

Vision

We will be the Industrial/White Biotech Specialists in finding and exploring high-value niches in our products business and novel solutions in our Science business. We will be much more agile than others and will always look to produce products in-house or with partners

Pioneering Bioproducts.

BRAIN Aktiengesellschaft Zwingenberg Germany http://www.brain-biotech.com +49 (0) 6251-9331-0

4

This is Brain

Brain AG

BioScienceBioIndustrial

Solutions & Services

Products

Breakthroughs

Stable Service Business with Upside

Innovation & Optimization

Own and Partnered NBD TMS BioActive Compound Libraries Enzymes Microorganisms Bioactives

~ 5m-7m Annual

~ 12m Annual Revenues*

~ 26m Annual Revenues

Cost-plus Contract research,

Investment

>10% EBITDA Margin*

Milestones, Technology & License Fees

*FY '18/'19

Pioneering Bioproducts.

BRAIN Aktiengesellschaft Zwingenberg Germany http://www.brain-biotech.com +49 (0) 6251-9331-0

5

Why Invest in BRAIN

Multiple Triggers for strong Revenue and Margin Growth

Pioneering Bioproducts.

BRAIN Aktiengesellschaft Zwingenberg Germany http://www.brain-biotech.com +49 (0) 6251-9331-0

6

BRAIN: At the Heart of UN Sustainable Development Goals

Our Products and Solutions address at least six Goals directly

Sugar Replacement

Sugar Taste Enhancer

Salt Replacement

Salt Taste Enhancer

Natural Aromas

Anti-Microbials Wound Treatment

Natural Preservatives Bioactive Plant Cosmetics

Green Mining

Phosphate Recycling

Green Mining Microbial CO2 Usage

Biological Production

Urban Mining

Improving Production Efficiencies

Fermented Food from Sidestreams

Pioneering Bioproducts.

BRAIN Aktiengesellschaft Zwingenberg Germany

http://www.brain-biotech.com +49 (0) 6251-9331-0

7

Our Targets

This FY

Read the original:
BRAIN Biotechnology Research and Information Network : BRAIN - Investor Presentation - Marketscreener.com

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the biliary tract cancers cohort of the ongoing SUMMIT trial of neratinib at the virtual 2021 Gastrointestinal Cancers Symposium hosted by the American Society of Clinical Oncology (ASCO GI) that is currently taking place. The presentation, entitled, Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT basket trial, is being presented at a Poster Session by James J. Harding, MD, Regional Director, Early Drug Development, Memorial Sloan Kettering Cancer Center, an investigator of the trial. A copy of this poster presentation is available on the Puma website.

The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study that included a cohort evaluating the safety and efficacy of neratinib administered daily to patients who have HER2 (ERBB2) mutation-positive advanced biliary cancer. Patients received 240 mg of neratinib daily as a single agent.

In this cohort of 25 patients, 11 patients had cholangiocarcinoma, 10 patients had cancer of the gallbladder and 4 patients had cancer of the ampulla of Vater. 24 patients had received prior systemic chemotherapy with a median of 2 prior lines of therapy (range 0-7) before entering the trial.

The efficacy results from the trial demonstrated that there were 4 patients with confirmed partial responses (3 patients with cancer of the gallbladder and 1 patient with cholangiocarcinoma) and an additional 3 patients who had stable disease lasting 16 weeks (1 patient with cancer of the ampulla of Vater and 2 patients with cholangiocarcinoma, one of which remained on treatment for 56 weeks before progression). This resulted in an objective response rate of 16% and a clinical benefit rate of 28%. The durations of response were 3.0 months, 3.7 months, and 4.7 months and additionally one patient with gallbladder cancer remains on treatment >80 weeks.

The safety profile of patients with biliary tract tumors is similar to that previously reported for patients treated with neratinib monotherapy and mandatory loperamide prophylaxis in the first 2 months; treatment was manageable, with 56% of patients experiencing some diarrhea, including 24% with grade 3 diarrhea. There were no episodes of grade 4 diarrhea, and no treatment discontinuations due to diarrhea. Four patients required neratinib dose reduction and one patient was hospitalized due to diarrhea.

We have shown neratinib to be safe and tolerable in these patients with advanced biliary tract tumors, and demonstrated activity comparable to current standards of care with similar progression-free survival and overall survival in these heavily pretreated patients, said Dr. Harding.

Alan H. Auerbach, CEO and President of Puma Biotechnology, added, We are very pleased with the preliminary activity seen with neratinib in this cohort of patients and specifically in patients with cancer of the gallbladder and cholangiocarcinoma.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Lactation: Advise women not to breastfeed.

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

See the article here:
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT Basket Trial of Neratinib at ASCO GI -...

Northampton, MA --News Direct-- Illumina

Were honored to be named to the prestigious 2021 Dow Jones Sustainability Indices for a third year in a row. Illumina received the highest score in the Pharmaceuticals, Biotechnology and Life Sciences industry.

Inclusion in the DJSI highlights our commitment to continuously improving and growing our Corporate Social Responsibility (CSR) program to build a more sustainable and equitable future for all. Our program focuses on accelerating access to genomics, supporting our communities, and integrating environmental stewardship into our operations.

If you would like to hear more about our CSR program, join us at our inaugural ESG Investor event on Tuesday Nov 16 at 11 am PT.

Thank you to all our employees for championing the needs of patients, customers, our communities, and our planet.

View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com

View source version on newsdirect.com: https://newsdirect.com/news/illumina-named-to-2021-dow-jones-sustainability-indices-with-highest-score-in-pharmaceuticals-biotechnology-and-life-sciences-industry-107725996

See more here:
Illumina Named to 2021 Dow Jones Sustainability Indices With Highest Score in Pharmaceuticals, Biotechnology and Life Sciences Industry - Yahoo...

When I was looking for universities to apply for an undergraduate programme, I heard about Rabindranath Tagore University (RNTU) and decided to visit the campus. I was astonished to see all the facilities offered here. Since the educational institutions in and around Vidisha dont offer similar facilities, I moved to Bhopal to join RNTU for a programme in Biotechnology.

This subject is used in different fields, including agriculture, environment and medicine and is slowly gaining popularity in India, especially in relation to agriculture, organic crops as well as cross breeding.

Infrastructure

At RNTU, we have access to excellent labs and equipment required for research, such as an in-house DNA fingerprinting lab and this makes the educational experience really engrossing.

Also, the teachers are supportive and helpful in creating an interactive learning experience. Presentations and audiovisual lessons and use of technology make the classes compelling.

The exposure to practical learning, as well as extracurricular activities, has improved my management and leadership skills. It has enabled me come out of my shell and explore the world as well as my own capabilities. One of my best experiences was representing my university at a national level debate competition organised by the Amity University, Lucknow.

In addition to participating in competitions, I was also a part of the volunteering committee at Vishwa Rang, the Tagore International Literature and Arts Festival during which I met and interacted with many artists and writers.

I was also a member of the organising team for the annual college festival Rhythm. We decided each act, divided the responsibilities and mapped of various activities with deadlines proper execution.

Even during the lockdown, we are constantly getting various internship opportunities so that our future is not adversely affected by the pandemic.

Kanika Soni is a third-year undergraduate student of Biotechnology from the Rabindranath Tagore University, Bhopal

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Move smoothly between articles as our pages load instantly.

Enjoy reading as many articles as you wish without any limitations.

A one-stop-shop for seeing the latest updates, and managing your preferences.

A select list of articles that match your interests and tastes.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Visit link:
Biotech and beyond - The Hindu

The 51 rating InvestorsObserver gives to Syros Pharmaceuticals Inc (SYRS) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 60 percent of stocks in the Biotechnology industry, SYRSs 51 overall rating means the stock scores better than 51 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 51 means the stock is more attractive than 51 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Syros Pharmaceuticals Inc (SYRS) stock is higher by 9.3% while the S&P 500 has fallen -0.66% as of 1:34 PM on Friday, Dec 18. SYRS has risen $1.03 from the previous closing price of $11.07 on volume of 392,085 shares. Over the past year the S&P 500 has gained 15.37% while SYRS has risen 94.53%. SYRS lost -$1.65 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Syros Pharmaceuticals Inc (SYRS) Stock.

Go here to read the rest:
Is Syros Pharmaceuticals Inc (SYRS) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The 45 rating InvestorsObserver gives to Alnylam Pharmaceuticals, Inc. (ALNY) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 46 percent of stocks in the Biotechnology industry, ALNYs 45 overall rating means the stock scores better than 45 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 45 means the stock is more attractive than 45 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Alnylam Pharmaceuticals, Inc. (ALNY) stock is trading at $144.75 as of 10:40 AM on Friday, Jan 8, a rise of $5.35, or 3.84% from the previous closing price of $139.40. The stock has traded between $137.72 and $145.09 so far today. Volume today is low. So far 103,431 shares have traded compared to average volume of 509,366 shares.

Click Here to get the full Stock Score Report on Alnylam Pharmaceuticals, Inc. (ALNY) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See the article here:
Is Alnylam Pharmaceuticals, Inc. (ALNY) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics, Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: ^NBI). Repares addition to the NBI will become effective prior to market open on Monday, December 21, 2020.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.

For more information about the NASDAQ Biotechnology Index, including eligibility criteria, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-state precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Companys pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Pol inhibitor programs. For more information, please visit reparerx.com.

SNIPRx is a registered trademark of Repare Therapeutics, Inc.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are forward-looking statements. These statements may be identified by words such as aims, anticipates, believes, could, estimates, expects, forecasts, goal, intends, may, plans, possible, potential, seeks, will and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the discovery of potential product candidates using SNIPRx platform; and the clinical development of the Companys pipeline and its research and development programs, including the anticipated timing of its clinical trials of RP-3500 and RP-6306; and the development of preclinical assets pursuant to the Companys collaboration with Bristol Myers Squibb. These forward-looking statements are based on the Companys expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Companys clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including the impacts of the COVID-19 pandemic on the Companys business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause the Companys actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled "Risk Factors" in the Companys Quarterly Report on Form 10-Q for the period ended September 30, 2020 filed with the Securities and Exchange Commission (the SEC) on November 12, 2020, and its subsequent filings with the SEC. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

View original post here:
Repare Therapeutics Added to the NASDAQ Biotechnology Index - Business Wire

Market Study Report, LLC adds latest research report on Food Biotechnology Industry Market, which delivers a comprehensive study on current industry trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrates its growth trends and competitive landscape as well as the key players in the business.

This Food Biotechnology Industry market research study is a collection of insights that translate into a gist of this industry. It is explained in terms of a plethora of factors, some of which include the present scenario of this marketplace in tandem with the industry scenario over the forecast timeframe.

Request a sample Report of Food Biotechnology Industry Market at:https://www.marketstudyreport.com/request-a-sample/2727907?utm_source=cheshire.media&utm_medium=Ram

The report is also inclusive of some of the major development trends that characterize the Food Biotechnology Industry market. A comprehensive document in itself, the Food Biotechnology Industry market research study also contains numerous other pointers such as the current industry policies in conjunction with the topographical industry layout characteristics. Also, the Food Biotechnology Industry market study is comprised of parameters such as the impact of the current market scenario on investors.

The pros and cons of the enterprise products, a detailed scientific analysis pertaining to the raw material as well as industry downstream buyers, in conjunction with a gist of the enterprise competition trends are some of the other aspects included in this report.

How has the competitive landscape of this industry been categorized?

, as per the report.

Regional landscape: How will the details provided in the report help prominent stakeholders?

Ask for Discount on Food Biotechnology Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2727907?utm_source=cheshire.media&utm_medium=Ram

Other pivotal aspects encompassed in the Food Biotechnology Industry market study:

.

.

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-food-biotechnology-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. Global Sales Forecasting Software Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-sales-forecasting-software-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

2. Global Application Performance Monitoring (APM) Suites Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-application-performance-monitoring-apm-suites-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Read More Reports On: https://www.marketwatch.com/press-release/copper-chlorophyll-market-segmented-by-product-top-manufacturers-geography-trends-forecasts-to-2025-2020-12-03

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the original post:
Food Biotechnology Industry Market Growth Projection from 2020 to 2026 - Cheshire Media

A recently introduced Global Food Biotechnology Market report includes factors such as size, growth, share, industry trends and project its growth by 2026. This comprehensive study aims to provide an overview of with in-depth market breakdown by product type, application, end-user, and region and collect useful data for this extensive, commercial study of the Food Biotechnology market. Furthermore, in-depth competitive landscape, forecast, strategies import/export consumption, supply and demand figures, cost price and production value gross margins are also provided in the Food Biotechnology industry.

The TOP STANDING OUT COMPANIES profiled are:

ArcadiaBiosciencesMonsantoAquaBountyTechnologiesBayer CropScienceAGCamson Bio TechnologiesBASFPlantScienceHy-LineInternationalDowDuPontKWS GroupEvogeneLtdOrigin AgritechSyngenta AG

Get Sample PDF [emailprotected] https://www.reportsintellect.com/sample-request/1583730

The report highlights key growth strategies adopted by these players of the Food Biotechnology industry, including details such as financial overview, product/services offered, prominent developments, and value chain analysis. In the beginning of the report introduced the Food Biotechnology basics: definitions, classifications, applications and market overview. In the end, the report introduced new project SWOT analysis, investment feasibility and investment return analysis as well as the conclusion of the research study is provided.

Market Segmentation

Food Biotechnology Market by Type

Transgenic CropsSynthetic Biology Derived Products

Food Biotechnology Market by Application

AnimalsPlantsOther

Food Biotechnology Market by Geography

North America Country (United States, Canada)

South America

Asia Country (China, Japan, India, Korea)

Europe Country (Germany, UK, France, Italy)

Other Country (Middle East, Africa, GCC)

Major Points from Table of Contents:-

Chapter 1: Market Overview, Scope, Market risks, or systematic risks and Segment by Type, End-User & Major Regions Market Size

Chapter 2 analyses most eminent Players of the Food Biotechnology Market by sales, revenue etc for the Forecast period 2020 to 2026Chapter 3 Competitive landscape based on sales, revenue, volume, market share etc for the period 2020 to 2026.Chapter 4 illustrate the global market by regions and their market share, sales, revenue etc for the period to 2026.Chapters 5 to 9 analyse the Food Biotechnology regions with Food Biotechnology countries based on market share, revenue, sales etc.Chapter 10 and 11 contain the information concerning market basis types and application, sales market share, rate of growth etc for forecast period 2020 to 2026.Chapter 12 focuses on the market forecast for 2020 to 2026 for the Food Biotechnology Market by regions, type and application, sales and revenue, profit.Chapter 13 to 15 contain the transient details associate to sales channels, suppliers, traders, dealers, research findings and conclusion etc for the Food Biotechnology Market.

Get the discounted price for this report @ https://www.reportsintellect.com/discount-request/1583730

Questions Answered in the Food Biotechnology Market Report:

What You Can Expect From Our Report:

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to introduced the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.

So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:[emailprotected]Phone No: + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

Original post:
Food Biotechnology market performance to bolster in the forecast period | ArcadiaBiosciences, Monsanto, AquaBountyTechnologies, Bayer CropScienceAG -...